French biopharmaceutical company Adocia SA is seeking over $200 million more in damages from Eli Lilly and Co. in arbitration over an abandoned partnership on the diabetes treatment BioChaperone Lispro, adding claims that Lilly misused Adocia's trade secrets and breached confidentiality agreements.
The Fourth Circuit on Tuesday rejected Boston Scientific Corp.'s appeal of an $18.5 million verdict in a trial over injuries allegedly caused by its Obtryx pelvic mesh devices, saying the company had gotten a fair trial.
Valeant Pharmaceuticals International Inc. and others who were sued in Manhattan federal court by three investment funds over alleged fraud and price-gouging have asked the court to send the case to New Jersey, where it would be bundled with dozens of other similar suits.
The state of Alabama has hit Purdue Pharma LP with a lawsuit accusing the drugmaker of exacerbating the state’s opioid epidemic by marketing the drugs as safe to treat common chronic pain and downplaying the risk of addiction, Attorney General Steve Marshall said Tuesday.
A Maryland surgery center linked to a deadly meningitis outbreak involving contaminated epidural painkillers exchanged salvos Friday with the estate of a deceased patient in Massachusetts federal court multidistrict litigation over whether the estate was entitled to punitive damages under either of those states’ laws.
A former Kentucky doctor will serve eight years in prison after pleading guilty to nearly 50 charges of illegal distribution of opioids and health care fraud, the U.S. Department of Justice said Monday.
German drug and chemical maker Bayer AG on Friday sent Europe's antitrust enforcers a new set of commitments aimed at curing competitive concerns raised by its planned $63.5 billion buyout of U.S. agrochemical company Monsanto Co.
A Delaware federal magistrate judge Monday told Cornell University that the federal courts can’t restart a settled patent case over allegations it was defrauded by its own co-plaintiff.
A former Aveo Pharmaceuticals Inc. executive continued to argue in Massachusetts federal court Monday that he should not have to pay a fine or be barred from leadership positions over the Securities and Exchange Commission’s allegations that he deceived investors about Aveo's flagship kidney cancer drug, saying he had learned his lesson.
The Federal Circuit on Monday affirmed the dismissal of a declaratory judgment suit AbbVie filed seeking to invalidate a patent it licensed from MedImmune for use in the blockbuster drug Humira, ruling the suit can’t proceed because it wouldn’t resolve the companies’ license dispute.
Pfizer's consumer health unit reportedly only received bids by GlaxoSmithKline and Reckitt Benckiser Group, food processing giant Archer Daniels Midland is in talks to swallow rival commodities trader Bunge as soon as this week, and Bhushan Steel has received two bids for its business.
A Pennsylvania federal judge on Monday declined to free the Israeli branch of Teva Pharmaceuticals USA Inc. from an age discrimination suit brought by a senior facilities manager in the United States on grounds that the unit had significant control over American business operations.
A Massachusetts federal judge was asked Friday to preliminarily approve Vertex Pharmaceuticals Inc.’s $4.75 million settlement to end putative class action claims the company violated the Telephone Consumer Protection Act by faxing unsolicited invitations to an event about its hepatitis C therapy.
A Florida attorney who was chided by a Philadelphia judge last month for posting courtroom photos on social media with the inflammatory hashtag “#killinnazis" will not be involved in six upcoming trials over injuries allegedly caused by Bayer AG’s blood thinner Xarelto, according to an order docketed Friday.
The IRS on Friday defended its authority to deny tax credits to drug traffickers and urged the U.S. Supreme Court to deny an appeal by a Colorado marijuana company that argued the IRS lacks the power to investigate drug cases.
A California federal judge on Friday granted a motion by Genentech to toss a complaint brought by Amgen seeking to invalidate more than two dozen patents related to Genentech’s cancer treatment Avastin, finding that Amgen was bypassing a negotiation scheme required by law.
German bone cement manufacturer Heraeus Kulzer GmbH was dealt a blow by the Seventh Circuit on Thursday, which ruled the company had not appealed in a timely fashion in relation to a trade secrets dispute with competitor Biomet Inc.
Ten firms are guiding 10 companies scheduled to price 10 initial public offerings exceeding $1.8 billion during the week of Feb. 5, led by two energy services companies, marking a busy start to the month after a record-breaking January.
An investor who sued billionaire physician Patrick Soon-Shiong, for tapping $47 million from biotech Precision Biologics Inc. after he acquired control, rejected assurances Thursday of the value's return to the company and again asked Delaware's Chancery Court to place Precision under custodianship.
A retail business owner seeking to represent a class of Bayer AG customers failed to show that the company’s marketing of its “custom fit” Dr. Scholl’s shoe inserts was likely to mislead reasonable customers, the Second Circuit has said, affirming the case’s dismissal.
Federal courts across the country are handing down important rulings interpreting the U.S. Supreme Court’s landmark decision on False Claims Act liability in Universal Health Services v. Escobar. As the rulings keep pouring in, stay up to speed on Law360’s latest coverage and analysis of Escobar’s impact.
As we start the new year, Lawrence E. Ashery of Caesar Rivise PC looks back at the 12 most important patent law opinions of 2017.
After much hand-wringing in 2017 about whether Foreign Corrupt Practices Act enforcement would diminish radically under President Donald Trump, it’s now safe to say that all signs point toward continued and vigorous enforcement, say attorneys with Foley & Lardner LLP.
What business of law topics piqued reader interest in 2017? Take a look back at the year's five most-read legal industry articles from Law360 guest authors.
Two years ago, Federal Rule of Civil Procedure 37(e) was amended to provide a clearer road map for courts analyzing whether to permit sanctions for the spoliation of evidence. Yet there is still no specific guidance for when a sanctions request relates to electronically stored and nonelectronically stored information, says Skadden associate Robin Shah.
The U.S. Food and Drug Administration recently issued two draft guidance documents describing types of software functions it will not regulate. While the policy structure in this area is a work in progress, these documents continue the general trend toward relatively limited, risk-based FDA regulation of digital health software, say attorneys with Ropes & Gray LLP.
In Cleveland Clinic Foundation v. True Health Diagnostics, the Federal Circuit recently held that claims in a U.S. patent were not infringed under either contributory infringement or induced infringement, weighing the enforceability of single claims that cover the steps of both diagnosing and treating a patient, say Brian Amos and Alan Miller of Amster Rothstein & Ebenstein LLP.
Following the Federal Circuit's recent Amgen v. Sandoz holding on the Biologics Price Competition and Innovation Act, sponsors now know that applicants need not "dance." The decision of whether the patent dance happens will be a major inflection point in every biosimilars dispute, say Justin Weiner and Sara Margolis of MoloLamken LLP.
The last few months have seen increased enforcement activity related to the Foreign Corrupt Practices Act. Since August, the U.S. Securities and Exchange Commission and the U.S. Department of Justice have resolved more than 15 cases against corporations and individuals, issued several declinations, and initiated at least five new investigations, say Michael Skopets and James Tillen of Miller & Chevalier Ltd.
For many female attorneys, the results revealed in the New York State Bar Association’s recently adopted report on female litigators in the courtroom were not encouraging but not terribly surprising. Each stakeholder in the litigation process — judges, law firms and corporate clients — should contribute toward increasing female voices in the courtroom, says Carrie Cohen of Morrison & Foerster LLP.
As the U.S. shifts from a fee-for-service to a value-based health care system, telemedicine is viewed by many as the solution for achieving access to care and cost-efficiency. Kristi Kung and Matthew Shatzkes of Sheppard Mullin Richter & Hampton LLP look back on some of the telemedicine-related legal and regulatory changes that occurred in 2017 and discuss potential areas of interest in 2018.